Yield10 Bioscience Announces Warrant Exercises for Proceeds of $3.8 million
By Dr. Matthew Watson
WOBURN, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has received proceeds of approximately $3.8 million from the exercise of 472,099 warrants exercised between January 1, 2021 and February 16, 2021, and the Company has issued to investors 472,099 shares of common stock in exchange for the exercised warrants. The warrants were issued to investors pursuant to a public offering that closed on November 19, 2019. Since November 19, 2019, a total of 679,395 warrants issued in the public offering have been exercised for total proceeds of $5.4 million. The Series A and Series B warrants issued in the November 2019 public offering are exercisable at $8.00 per share and have expiration dates of May 19, 2022 and May 19, 2027, respectively.
View original post here:
Yield10 Bioscience Announces Warrant Exercises for Proceeds of $3.8 million
Related Post
- Progenity Presents Key Verification Study Data for Preecludia™ Preeclampsia Rule-out Test at the 2021 American College of Obstetricians and... - May 3rd, 2021
- Galapagos creates new subscription right plans - May 3rd, 2021
- ECMOHO Announces Fourth Quarter Unaudited Financial Results and Fiscal Year 2020 Audited Financial Results - May 3rd, 2021
- ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021 - May 3rd, 2021
- AnPac Bio Announces Filing of Annual Report on Form 20-F for 2020 - May 3rd, 2021
- Blueberries Medical Reports 2020 Financial Results - May 3rd, 2021
- Eve & Co Announces Financial Results for the Year Ended December 31, 2020 - May 3rd, 2021
- Shattuck Labs Announces Participation in Upcoming May Conferences - May 3rd, 2021
- Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in May - May 3rd, 2021
- Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases... - May 3rd, 2021
- Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept - May 3rd, 2021
- Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in... - May 3rd, 2021
- Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage... - May 3rd, 2021
- Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in... - May 3rd, 2021
- Telix Pharmaceuticals Appoints Mr. Richard Valeix as EMEA President - May 3rd, 2021
- Addex Therapeutics to Release Q1 2021 Financial Results and Host Conference Call on May 5, 2021 - May 3rd, 2021
- Genenta to Appoint Richard Slansky as CFO and Anthony Marucci as Board Member - May 3rd, 2021
- Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine - May 3rd, 2021
- Santhera Announces Settlement of Convertible Bond Exchange Offer on May 4, 2021 - May 3rd, 2021
- DBV Technologies Reports Q1 2021 Financial Results - May 3rd, 2021
- Fulgent Genetics to Announce First Quarter 2021 Financial Results on Thursday May 6, 2021 - April 19th, 2021
- Zogenix Presents New Data from a Study Highlighting the Impact of Treatment with FINTEPLA® (Fenfluramine) Oral Solution on Dravet Syndrome Patients,... - April 19th, 2021
- LIDDS Annual Report 2020 - April 19th, 2021
- Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021 - April 19th, 2021
- Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021 - April 19th, 2021
- Vistin Pharma ASA: Invitation to Q1 2021 conference call - April 19th, 2021
- Cosmos Holdings Reports Revenue Growth of 40% to a Record $55.4 Million and Achieves Profitability for 2020 - April 19th, 2021
- Sanofi completes Kiadis acquisition - April 19th, 2021
- Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking... - April 19th, 2021
- Virbac : Declaration of the number of shares and voting rights March 2021 - April 19th, 2021
- Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - April 19th, 2021
- AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020 - April 19th, 2021
- Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies... - April 19th, 2021
- Auxly Receives Approval to Begin Trading on the Toronto Stock Exchange April 20, 2021 - April 19th, 2021
- Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology... - April 19th, 2021
- VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking... - April 19th, 2021
- Number of Shares and Voting Rights of Innate Pharma as of April 1, 2021 - April 19th, 2021
- European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma - April 19th, 2021
- Nicox Provides First Quarter 2021 Business Update and Financial Highlights - April 19th, 2021
- ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer - April 19th, 2021
- Number of voting rights as of March 31, 2021 - April 4th, 2021
- Multiple Former FDA Commissioners Voice Support for Reduced Nicotine Mandate; Proposed Legislation Would Be Game-Changing for 22nd Century - April 4th, 2021
- OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine - April 4th, 2021
- Tauriga Sciences Inc. Completes the Translations of Its 25mg Tauri-Gum Blister Pack Into the Following Languages: Mandarin Chinese, Japanese, Arabic,... - April 4th, 2021
- Autolus Therapeutics to Participate in Investor Conferences Through April - April 4th, 2021
- Syneos Health Schedules First Quarter 2021 Earnings Call for Thursday, April 29, 2021 - April 4th, 2021
- AgraFlora Announces Definitive Agreement to Sell its AAA Heidelberg Subsidiary - April 4th, 2021
- GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate Update - April 4th, 2021
- Neuronetics Announces Appointment of Robert Cascella to its Board of Directors - April 4th, 2021
- Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021 - April 4th, 2021
- Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 4th, 2021
- NKMax America Announces Corporate Name Change to NKGen Biotech - April 4th, 2021
- Leading BioSciences Releases Video Message Highlighting Compelling Investment Thesis of Proposed Merger with Seneca Biopharma, Inc. - April 4th, 2021
- Valneva - Déclaration d’actions et de droits de vote – Mars 2021 - April 4th, 2021
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 4th, 2021
- ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021 - April 4th, 2021
- Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings - April 4th, 2021
- DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors - April 4th, 2021
- Concerns about alcohol-based sanitisers are changing the way hospitals invest in protecting their staff - April 4th, 2021
- Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD - April 4th, 2021
- Gritstone Announces Promotions Within its Leadership Team - March 8th, 2021
- Spectral Medical Announces the Appointment of Chris Seto to CEO - March 8th, 2021
- Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity - March 8th, 2021
- Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease - March 8th, 2021
- Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference - March 8th, 2021
- Silo Wellness Kicks Off Second Oregon Psychedelic Wellness Retreat - March 8th, 2021
- TRACON Pharmaceuticals Announces Appointment of Lisa Johnson-Pratt, M.D., to its Board of Directors - March 8th, 2021
- Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic... - March 8th, 2021
- Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board - March 8th, 2021
- Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference - March 8th, 2021
- Medexus to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021 - March 8th, 2021
- XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection - March 8th, 2021
- AXIM® Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test - March 8th, 2021
- Fierce Medtech Names Canary Medical a “Fierce 15” Company for 2020 - March 8th, 2021
- INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021 - March 8th, 2021
- AgraFlora Appoints Elise Coppens as New CEO and Director to Implement the Next Phase of its Corporate Strategy - March 8th, 2021
- AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study - March 8th, 2021
- Cytovia Therapeutics’ Management to Present at Three Upcoming Conferences in March - March 8th, 2021
- Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s... - March 8th, 2021
- Global WholeHealth Partners Corp (OTC:GWHP) to Announce that Global is Now Offering the AstraZeneca Vaccines as Mentioned in 8K Filing on 03/02/21 - March 8th, 2021
Global News Feed
Comments Off on Yield10 Bioscience Announces Warrant Exercises for Proceeds of $3.8 million |
February 19th, 2021
This author published 3792 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research